Drug Manufacturing

Ampersand Capital acquires Purna Pharmaceuticals

Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector.

DeepHow introduces PharmaCloud for pharmaceutical manufacturers

DeepHow has launched PharmaCloud, a good manufacturing practice (GMP)-compliant cloud environment developed specifically to standardise AI-driven operator training in pharma manufacturing.

iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s

iRegene Therapeutics has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its lead product, NouvNeu001, aimed at treating Parkinson’s disease.

AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy

AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

Novartis to build fourth US radioligand therapy facility in Florida

Novartis has announced plans to construct a radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its ongoing radioligand therapy manufacturing expansion.

MediLink and Roche announce exclusive licensing agreement for YL201c

MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of YL201, an investigational antibody-drug conjugate (ADC) targeting B7H3 in various solid tumour types.

Samsung Biologics to acquire Human Genome Sciences

Samsung Biologics has entered into a definitive agreement, through its subsidiary Samsung Biologics America, to acquire Human Genome Sciences from GSK as part of its plan to expand manufacturing capabilities in the US.

J&J receives FDA approval for lung cancer therapy

Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneously (SC) administered therapy to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

EC approves Incyte’s Minjuvi combo for follicular lymphoma

The European Commission (EC) has approved Incyte’s Minjuvi (tafasitamab) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) who have received a minimum of one systemic therapy line.